The next‐generation sequencing of tumors from patients with EGFR‐mutated squamous cell lung carcinoma who did not respond to osimertinib showed the amplification of TP53, R158L, CDK6, and KRAS. Here, KRAS is linked to squamous cell lung carcinoma.